Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1997-03-20
1999-04-06
Shah, Mukund J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
514220, 514221, 540493, 540495, 540500, A61K 3155, C07D24310
Patent
active
058918710
ABSTRACT:
The invention relates to substituted 2,3-benzodiazepin-4-ones which are antagonists or positive modulators of AMPA receptors, and the use thereof for treating, preventing or ameliorating neuronal loss associated with stroke, global and focal ischemia, CNS trauma, hypoglycemia and surgery, as well as treating or ameliorating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease and Down's syndrome, treating, preventing or ameliorating the adverse consequences of the overstimulation of the excitatory amino acids, treating or ameliorating anxiety, psychosis, convulsions, chronic pain, glaucoma, CMV retinitis, urinary incontinence, muscular spasm and inducing anesthesia, as well as for treating or ameliorating the adverse consequences of excitatory amino acid deficiency such as schizophrenia, Alzheimer's disease and malnutrition and neural maldevelopment, and as cognition enhancers. The invention also is directed to the process for the preparation of the substituted 2,3-benzodiazepin-4-ones.
REFERENCES:
patent: 4614740 (1986-09-01), Lang et al.
patent: 4835152 (1989-05-01), Korosi et al.
patent: 5550124 (1996-08-01), Gee
Anderson, B.A. et al., "Application of a Practical Biocatalytic Reduction to an Enantioselective Synthesis of the 5H-2,3-Benzodiazepine LY300164," J. Am. Chem. Soc. 117:12358-12359 (Dec. 1995).
Buchan, A.M. et al., "AMPA Antagonists: Do They Hold More Promise for Clinical Stroke Trials Than NMDA Antagonists?" Stroke 24(Suppl. I):I-148-I-152 (1993).
De Sarro, G. et al., "GYKI 52466 and related 2,3-benzodiazepines as anticonvulsant agents in DBA/2 mice," Eur. J. Phamacol. 294:411-422 (Dec. 1995).
Gatta, F. et al., "Derivatives of 2,3-Benzodiazepine," IL Farmaco-Ed. Sc. 40:942-955 (1985).
Keana, J.F.W. et al., "Synthesis and Structure-Activity Relationships of Substituted 1,4-Dihydroquinoxaline-2,3-diones: Antagonists of N-Methyl-D-aspartate (NMDA) Receptor Glycine Sites and Non-NMDA Glutamate Receptors," J. Med. Chem. 38:4367-4379 (Oct. 1995).
Larson, J. et al., "Effects of an AMPA receptor modulator on methamphetamine-induced hyperactivity in rats," Brain Res. 738:353-356 (Nov. 1996).
Sheardown, M.J. et al., "AMPA, but not NMDA, receptor antagonism is neuroprotective in gerbil global ischaemia, even when delayed 24 h," Eur. J. Pharm. 236:347-353 (1993).
Staubli, U. et al., "Facilitation of glutamate receptors enhances memory," Proc. Natl. Acad. Sci. USA 91:777-781 (1994).
Thomas, R.J., "Excitatory Amino Acids in Health and Disease," JAGS 43:1279-1289 (Nov. 1995).
Bennett, M.V.L. et al., "The GluR2 Hypothesis: Ca.sup.++ -permeable AMPA Receptors in Delayed Neurodegeneration," Cold Spring Harbor Symposia on Quantitative Biology LXI:373-384 (Jun. 1996).
Blin, O., "Should N-Methyl-D-Aspartate or Non-N-Methyl-D-Aspartate Glutamate Receptor Antagonists Be Used in Amyotrophic Lateral Sclerosis?," in: Pathogenesis and Therapy of Amyotrophic Lateral Sclerosis, Serratrice, G. and T. Musat, eds., Lippincott-Raven Publishers, Philadelphia, PA, pp. 259-261 (1995).
Graham, S.H. et al., "A Dose-Response Study of Neuroprotection Using the AMPA Antagonist NBQX in Rat Focal Cerebral Ischemia," J. Pharmacology & Exper. Therapeutics 276:1-4 (Jan. 1996).
Hunter, J.C. and L. Singh, "Role of excitatory amino acid receptors in the mediation of the nociceptive response to formalin in the rat," Neurosci. Letters 174:217-221 (1994).
Johnson, S.A. et al., "Antagonism of Methamphetamine-Induced Hyperactivity in Rats by Specific Facilitation of AMPA-Receptor-Mediated Glutamatergic Transmission," Soc. Neurosci. 22:1676, Abstract No. 657.12 (1996).
Karcz-Kubicha, M. and S. Liljequist, "Evidence for an anxiogenic action of AMPA receptor antagonists in the plus-maze test," Eur. J. Pharmacol. 279:171-177 (Jun. 1995).
Lynch, G. et al., "Evidence That a Positive Modulator of AMPA-Type Glutamate Receptors Improves Delayed Recall in Aged Humans," Exper. Neurol.145:89-92 (May 1997).
Palmer, L.C. et al., "Evidence That Positive Modulators of AMPA Receptors Increase Aggregate Neuronal Activity in Neocortex Relative to Striatum: Relevance to Schizophrenia," IBC's Second Intl. Symposium on Schizophrenia: Latest Advances in Understanding and Drug Development, Philadelphia, PA (Jun. 1996).
Schuller, J.J. and J.F. Marshall, "Intrastriatal DNQX induces rotation and pallidal Fos in the 6-OHDA model of Parkinson's disease," NeuroReport 6:2594-2598 (Dec. 1995).
Yamakura, T. et al., "The sensitivity of AMPA-selective glutamate receptor channels to pentobarbital is determined by a single amino acid residue of the .alpha.2 subunit," FEBS Letters 374:412-414 (Nov. 1995).
Yoshiyama, M. et al., "Effects of GYKI 52466 and CNQX, AMPA/kainate receptor antagonists, on the micturition reflex in the rat," Brain Res. 691:185-194 (Sep. 1995).
Gatta et al., Chromium Trioxide Oxidation Products From 4-Spiro-1-Phenylisochromans, Journal of Heteocyclic Chemistry, vol. 20, No. 5, pp. 1267-1270, Sep. 1983.
Tomori et al., Pharmacokinetic and Metabolism Studies on Girisopam by Chromatographic and Spectrometric Methods in Humans, Journal of Chromatography, vol. 578, pp. 91-101, 1992.
Pelaggi et al., Electronic and Conformational Properties of 2,3-Benzodiazepine Derivatives, STN Printout, 1996.
Flammang, 2,3-Benzodiazepines: 2-Amino-3-Isoquinolinones From Ring Contraction of 4-oxo-2,3-Benzodiazepines, STN Printout, 1980.
Flammang et al., 2,3-Benzodiazepine Systems, STN Printout, 1976. STN Printout, 1972.
Beal, Aging, Energy, and Oxidative Stress in Neurodegenerative Diseases, Ann. Neurol., vol. 38, pp. 357-366, 1995.
Cai Sui Xiong
Field George
Lan Nancy C.
Wang Yan
Xia Haiji
Cocensys Inc.
Coleman Brenda
Shah Mukund J.
LandOfFree
Substituted 2,3-benzodiazepin-4-ones and the use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted 2,3-benzodiazepin-4-ones and the use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted 2,3-benzodiazepin-4-ones and the use thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1371522